Some clinical studies also support an increased incidence of anxiety diagnosis after GLP-1 analogs, with a more pronounced impact on women (hazard ratio of 2.19 vs 1.89 in women and men, respectively) (99), although more research evaluating this question in preclinical and clinical settings is needed for a more robust conclusion. This evidence concerns the gene GLP1R and Anxiety.